United States | Press Center
January 21, 2010
Canadian Company Responds to Haiti Earthquake Relief Efforts with $2 Million of Much Needed Medicines
Toronto, ON - The shipment of medicines included painkillers and antibiotics and is slated to leave this Saturday on an Air Canada flight. An earlier shipment left with a group of 10 doctors working for the relief organization "Feed the Children". The shipment of medicines included painkillers and antibiotics and is slated to leave this Saturday on an Air Canada flight. An earlier shipment left with a group of 10 doctors working for the relief organization "Feed the Children".
October 20, 2009
Apotex to Distribute Important Transdermal System for Management of Chronic Pain in the U.S. Market
Weston, FL - Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's recently FDA approved matrix Fentanyl Transdermal System for the management of chronic pain. The Fentanyl Transdermal System, developed by Hisamitsu, is manufactured at the company's state of the art Carlsbad, California facility. The total Fentanyl patch market in the U.S. represents approximately $1.2 billion in sales.
September 18, 2009
Second Shipment Of Life-Saving Aids Drug Leaving For Africa
Toronto, ON - Apotex Inc. today announced that the second shipment of Apo-TriAvir, the generic triple-combination AIDS drug produced to simplify AIDS treatment in developing countries, was leaving for Rwanda, the only country to have benefited from Canada's Access to Medicines Regime (CAMR). CAMR was created by Parliament more than 5 years ago, but because of the costly and complicated process it requires, no other company has come forward to participate in producing more affordable, life-saving generic drugs for export to developing countries.
September 8, 2009
FDA Pharmaceutical Import Alert
Toronto, ON - Apotex today issued the following statement concerning an Import Alert issued by the US Food and Drug Administration: The Import Alert recently posted by FDA applies to products manufactured at 2 of Apotex's many facilities. This alert relates to observations made following routine audits for products destined to the US only. We are actively working with the FDA to resolve the identified concerns as quickly as possible, and are optimistic that there will be a prompt resolution.
December 12, 2008
Appeals Court Affirms Plavix® Patent
Weston, FL - Apotex Corp. announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) in the case of Bristol Myers Squib/Sanofi v. Apotex, Inc. has found that U.S. Patent 4,847,265 (the '265 patent) covering Plavix® is valid and enforceable. The ruling upholds the U.S. District Court for the Southern District of New York's June 2007 decision regarding the '265 patent. The '265 patent covers clopidogrel bisulfate, the active ingredient in Plavix®. Apotex will simultaneously pursue a rehearing / rehearing en banc of today's decision.
May 7, 2008
Canadian Company Receives Final Tender Approval From Rwanda For Vital AIDS Drug
Toronto, ON - Apotex Inc., Canada's largest generic pharmaceutical company has successfully bid and been awarded a tender from the Rwandan Government for the life saving triple combination AIDS drug "Apo Triavir". Apotex is the first company to provide this medicine to Africa under the provisions of the Canadian Access to Medicines Regime (CAMR).
May 24, 2007
Apotex Launches Generic Norvasc®
Weston, FL - Apotex Corp. announced today that it has launched amlodipine besylate tablets (2.5 mg, 5 mg, and 10 mg), the generic equivalent of Pfizer's Norvasc®. The launch follows Monday's issuance of the mandate by the US Court of Appeals for the Federal Circuit's decision of March 22 invalidating Pfizer's US Patent 4,879,303 (the '303 patent) covering amlodipine besylate. The decision came in an action brought by Pfizer against Apotex. Apotex successfully invalidated the Pfizer patent.
March 21, 2007
Apotex Invalidates Norvasc® Patent
Weston, FL - Apotex Corp. announced today the Federal Circuit Court of Appeals in the case of Pfizer, Inc. v. Apotex, Inc. reversed a trial court's ruling and found that Pfizer's U.S. Patent 4,879,303 (the '303 patent) covering the Pfizer product Norvasc® was invalid. The '303 patent covers amlodipine besylate the active ingredient in Norvasc® as well as tablets made from amlodipine besylate. Because the limiting patent expires in two days, no company will have exclusivity over the product. Apotex expects to launch the product in the very near future.
August 31, 2006
Court Halts Sales of Generic Plavix®
Weston, FL - Apotex Corp. today announced that the U.S. District Court of the Southern District of New York has granted the request of Bristol Myers Squibb and Sanofi to issue a preliminary injunction to prevent further sales of Apotex's generic version of Sanofi's Plavix® (clopidogrel 75mg tablets). The Court denied BMS and Sanofi's request to force Apotex to recall product it has already shipped.
August 8, 2006
Apotex Launches First Generic Plavix®
Weston, FL - Apotex Corp. announced that it has today launched clopidogrel bisulfate 75 mg tablets. Clopidogrel is the generic equivalent of Sanofi's Plavix®, which is marketed in the U.S. by Bristol Myers Squibb.
January 25, 2006
Apotex Receives Approval for First Generic Plavix®
Weston, FL - Apotex Corp. today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clopidogrel bisulfate 75 mg tablets.